Minikes Alexander M, Liu Pei, Wang Hua, Hu Jiachen, Alwaseem Hanan, Li Yueming, Jiang Xuejun
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Peking University International Cancer Institute, Peking University Cancer Hospital and Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing 100191, China; Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
Mol Cell. 2025 Jul 15. doi: 10.1016/j.molcel.2025.07.001.
Ferroptosis, a metabolic cell death process driven by iron-dependent phospholipid peroxidation, is implicated in various pathologies, including cancer. While metabolic factors such as glucose, lipids, and multiple amino acids have all been demonstrated to modulate ferroptosis, the role of oxygen, another fundamental metabolic component, in ferroptosis is not fully understood. Here, we show that cells acclimated to a low oxygen environment develop marked resistance to ferroptosis, and this resistance is independent of canonical oxygen-sensing pathway mediated by prolyl hydroxylases (PHDs) and HIF transcription factors. Instead, hypoxia suppresses ferroptosis by inhibiting KDM6A, a tumor suppressor and oxygen-dependent histone demethylase, leading to reduced expression of its transcriptional targets, including lipid metabolic enzymes ACSL4 and ETNK1, thus rewiring cellular phospholipid profile to a ferroptosis-resistant state. Relevant to cancer, pharmacological inhibition of the oncogenic histone methyltransferase EZH2, which opposes KDM6A activity, restored ferroptosis sensitivity of xenograft bladder tumor tissues harboring KDM6A mutation.
铁死亡是一种由铁依赖性磷脂过氧化驱动的代谢性细胞死亡过程,与包括癌症在内的多种病理状况有关。虽然葡萄糖、脂质和多种氨基酸等代谢因子均已被证明可调节铁死亡,但氧气作为另一种基本的代谢成分,在铁死亡中的作用尚未完全明确。在此,我们发现适应低氧环境的细胞对铁死亡产生显著抗性,且这种抗性独立于脯氨酰羟化酶(PHD)和HIF转录因子介导的经典氧感应途径。相反,缺氧通过抑制肿瘤抑制因子和氧依赖性组蛋白去甲基化酶KDM6A来抑制铁死亡,导致其转录靶点(包括脂质代谢酶ACSL4和ETNK1)的表达降低,从而将细胞磷脂谱重编程为抗铁死亡状态。与癌症相关的是,对与KDM6A活性相反的致癌组蛋白甲基转移酶EZH2的药理学抑制,恢复了携带KDM6A突变的异种移植膀胱肿瘤组织的铁死亡敏感性。